Related Experiment Video
Updated: Apr 13, 2026

Small Bowel Transplantation In Mice
Published on: August 20, 2007
Primary intestinal lymphangiectasia treated with rapamycin in a child with tuberous sclerosis complex (TSC)
Sarah F Pollack1, Alexandra L Geffrey1, Elizabeth A Thiele1
1Department of Neurology, Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, Boston, Massachusetts.
Insights
Primary intestinal lymphangiectasia, a rare protein-losing enteropathy, was observed in a patient with tuberous sclerosis complex (TSC). Treatment with an mTOR inhibitor, rapamycin, effectively improved symptoms and normalized elevated VEGF-C levels.
Area of Science:
- Genetics
- Gastroenterology
- Oncology
Background:
- Tuberous sclerosis complex (TSC) is a genetic disorder affecting multiple organs, with known lymphatic system involvement.
- Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy due to lymphatic malformations.
Observation:
- This report details the first case of PIL in a patient with TSC, specifically a female with a TSC2 mutation.
- The patient presented with severe abdominal distension and chronic diarrhea in infancy.
Findings:
- Treatment with an mTOR inhibitor, rapamycin, led to significant clinical improvement.
- Rapamycin normalized elevated VEGF-C levels, a marker associated with lymphatic abnormalities.
Implications:
- PIL may be a rare manifestation of TSC, expanding the known clinical spectrum of the disorder.
- mTOR inhibitors show promise for treating this rare combination of conditions, suggesting a therapeutic role in future studies.
Abstract:
Primary intestinal lymphangiectasia (PIL) is a rare protein-losing enteropathy characterized by a congenital malformation of the lymphatic vessels of the small intestine causing insufficient drainage and leakage of lymph fluid. Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by benign hamartomas in multiple organ systems. While the lymphatic system has been implicated in TSC through lymphangioleiomyomatosis (LAM) and lymphedema, this paper reports the first case of PIL in TSC, a female patient with a TSC2 mutation. She developed persistent and significant abdominal distension with chronic diarrhea during her first year of life. Due to lack of treatment options and the involvement of the mTOR pathway in TSC, a trial of an mTOR inhibitor, rapamycin, was initiated. This treatment was highly effective, with improvement in clinical symptoms of PIL as well as abnormal laboratory values including VEGF-C, which was elevated to over seven times the normal upper limit before treatment. This case suggests that PIL is a rare manifestation of TSC, warranting the use of mTOR inhibitors in future studies.
More Related Videos
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
08:25A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment
Published on: June 10, 2025